315 related articles for article (PubMed ID: 34720591)
1. Targeted Therapy for Advanced or Metastatic Cholangiocarcinoma: Focus on the Clinical Potential of Infigratinib.
Yu J; Mahipal A; Kim R
Onco Targets Ther; 2021; 14():5145-5160. PubMed ID: 34720591
[TBL] [Abstract][Full Text] [Related]
2. Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements.
White K; Anwar AI; Jin K; Bollich V; Kelkar RA; Talbot NC; Klapper RJ; Ahmadzadeh S; Viswanath O; Varrassi G; Shekoohi S; Kaye AD
Cureus; 2023 Oct; 15(10):e46792. PubMed ID: 37954763
[TBL] [Abstract][Full Text] [Related]
3. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study.
Javle M; Roychowdhury S; Kelley RK; Sadeghi S; Macarulla T; Weiss KH; Waldschmidt DT; Goyal L; Borbath I; El-Khoueiry A; Borad MJ; Yong WP; Philip PA; Bitzer M; Tanasanvimon S; Li A; Pande A; Soifer HS; Shepherd SP; Moran S; Zhu AX; Bekaii-Saab TS; Abou-Alfa GK
Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):803-815. PubMed ID: 34358484
[TBL] [Abstract][Full Text] [Related]
4. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma.
Botrus G; Raman P; Oliver T; Bekaii-Saab T
Expert Opin Investig Drugs; 2021 Apr; 30(4):309-316. PubMed ID: 33307867
[TBL] [Abstract][Full Text] [Related]
5. Infigratinib in patients with advanced cholangiocarcinoma with
Makawita S; K Abou-Alfa G; Roychowdhury S; Sadeghi S; Borbath I; Goyal L; Cohn A; Lamarca A; Oh DY; Macarulla T; T Shroff R; Howland M; Li A; Cho T; Pande A; Javle M
Future Oncol; 2020 Oct; 16(30):2375-2384. PubMed ID: 32580579
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
[TBL] [Abstract][Full Text] [Related]
7. Infigratinib for cholangiocarcinoma.
Sadeghi S
Drugs Today (Barc); 2022 Jul; 58(7):327-334. PubMed ID: 35851868
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality.
Jain NK; Tailang M; Thangavel N; Makeen HA; Albratty M; Najmi A; Alhazmi HA; Zoghebi K; Alagusundaram M; Jain HK; Chandrasekaran B
Acta Pharm; 2024 Mar; 74(1):1-36. PubMed ID: 38554385
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations.
Lee PC; Hendifar A; Osipov A; Cho M; Li D; Gong J
Cancers (Basel); 2021 Apr; 13(7):. PubMed ID: 33916849
[TBL] [Abstract][Full Text] [Related]
10. FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice.
Kommalapati A; Tella SH; Borad M; Javle M; Mahipal A
Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34199304
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor (FGFR) inhibitors in cholangiocarcinoma: current status, insight on resistance mechanisms and toxicity management.
Chakrabarti S; Finnes HD; Mahipal A
Expert Opin Drug Metab Toxicol; 2022 Jan; 18(1):85-98. PubMed ID: 35129006
[TBL] [Abstract][Full Text] [Related]
12. The future of fibroblast growth factor receptor inhibitors and mechanisms of resistance for cholangiocarcinoma.
Ruff SM; Roychowdhury S; Pawlik TM
Expert Opin Pharmacother; 2023 May; 24(7):779-788. PubMed ID: 37042129
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas.
Wekking D; Pretta A; Martella S; D'Agata AP; Joeun Choe J; Denaro N; Solinas C; Scartozzi M
Heliyon; 2023 Sep; 9(9):e19541. PubMed ID: 37681152
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting.
Salati M; Caputo F; Baldessari C; Carotenuto P; Messina M; Caramaschi S; Dominici M; Bonetti LR
Cancer Manag Res; 2021; 13():7747-7757. PubMed ID: 34675670
[TBL] [Abstract][Full Text] [Related]
15. Infigratinib: First Approval.
Kang C
Drugs; 2021 Jul; 81(11):1355-1360. PubMed ID: 34279850
[TBL] [Abstract][Full Text] [Related]
16. Precision approaches for cholangiocarcinoma: progress in clinical trials and beyond.
Uson Junior PLS; Borad MJ
Expert Opin Investig Drugs; 2022 Jan; 31(1):125-131. PubMed ID: 34904492
[TBL] [Abstract][Full Text] [Related]
17. Targeting FGFR in intrahepatic cholangiocarcinoma [iCCA]: leading the way for precision medicine in biliary tract cancer [BTC]?
Aitcheson G; Mahipal A; John BV
Expert Opin Investig Drugs; 2021 Apr; 30(4):463-477. PubMed ID: 33678096
[No Abstract] [Full Text] [Related]
18. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1-3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3-altered Advanced/Metastatic Urothelial Carcinoma.
Lyou Y; Grivas P; Rosenberg JE; Hoffman-Censits J; Quinn DI; P Petrylak D; Galsky M; Vaishampayan U; De Giorgi U; Gupta S; Burris H; Rearden J; Li A; Wang H; Reyes M; Moran S; Daneshmand S; Bajorin D; Pal SK
Eur Urol; 2020 Dec; 78(6):916-924. PubMed ID: 32847703
[TBL] [Abstract][Full Text] [Related]
20. Pemigatinib: Hot topics behind the first approval of a targeted therapy in cholangiocarcinoma.
Rizzo A; Ricci AD; Brandi G
Cancer Treat Res Commun; 2021; 27():100337. PubMed ID: 33611090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
